281 related articles for article (PubMed ID: 21288332)
1. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
Lamy PJ; Fina F; Bascoul-Mollevi C; Laberenne AC; Martin PM; Ouafik L; Jacot W
Breast Cancer Res; 2011 Feb; 13(1):R15. PubMed ID: 21288332
[TBL] [Abstract][Full Text] [Related]
2. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
[TBL] [Abstract][Full Text] [Related]
3. The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.
Jacot W; Fiche M; Zaman K; Wolfer A; Lamy PJ
Biochim Biophys Acta; 2013 Aug; 1836(1):146-57. PubMed ID: 23628726
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
Arriola E; Marchio C; Tan DS; Drury SC; Lambros MB; Natrajan R; Rodriguez-Pinilla SM; Mackay A; Tamber N; Fenwick K; Jones C; Dowsett M; Ashworth A; Reis-Filho JS
Lab Invest; 2008 May; 88(5):491-503. PubMed ID: 18332872
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
6. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
[TBL] [Abstract][Full Text] [Related]
7. TOP2A gene copy number change in breast cancer.
Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
[TBL] [Abstract][Full Text] [Related]
10. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
Fasching PA; Weihbrecht S; Haeberle L; Gasparyan A; Villalobos IE; Ma Y; Ekici AB; Wachter DL; Hartmann A; Beckmann MW; Slamon DJ; Press MF
Breast Cancer Res Treat; 2014 May; 145(1):193-203. PubMed ID: 24682655
[TBL] [Abstract][Full Text] [Related]
11. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
12. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
[TBL] [Abstract][Full Text] [Related]
13. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
Sneige N; Hess KR; Multani AS; Gong Y; Ibrahim NK
Cancer; 2017 Apr; 123(7):1115-1123. PubMed ID: 27893937
[TBL] [Abstract][Full Text] [Related]
15. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
[TBL] [Abstract][Full Text] [Related]
16. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
Davies V; Voutsadakis IA
Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
[No Abstract] [Full Text] [Related]
17. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
[TBL] [Abstract][Full Text] [Related]
18. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.
Partanen L; Staaf J; Tanner M; Tuominen VJ; Borg Å; Isola J
Genes Chromosomes Cancer; 2012 Sep; 51(9):832-40. PubMed ID: 22585709
[TBL] [Abstract][Full Text] [Related]
19. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
[TBL] [Abstract][Full Text] [Related]
20. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
